AGI summary February 2006



Bridgehead International provides Experts’ Report for listing of AGI Therapeutics plc on AIM and IEX

AGI Therapeutics plc, announced its admission to trading on AIM and IEX in a €42.5 Million (£29.2 million) Placing on 27 February 2006, which was arranged by Davy. AGI is a specialty pharmaceutical company focused on gastrointestinal drug products derived from the Known Molecular Entity approach to drug re-profiling and development.

Bridgehead International carried out independent due diligence on behalf of AGI and Davy in the form of what is known as the 'Experts' Report', which was published in the Listing Document.

The publication of a report such as this satisfies regulatory requirements in certain cases, but it is the process leading up to its preparation that adds real value. Bridgehead’s expert consultants review many aspects of the Company's technical and commercial operations and, during the process, the Company and its Advisors gain an insight into concerns that potential investors are likely to have. The Company then has the opportunity, in advance of publication of the prospectus, either to take action to avoid these potential concerns or to have available the information or plans to address them.

Bridgehead is widely recognised as the leading provider of independent reports to support fundraising in the pharmaceutical and medical device fields in the UK, it has also worked with companies raising finance in the USA, Scandinavia and the Far East. Some of the companies that Bridgehead has reviewed as part of stock market listings and other investment rounds are: Lombard Medical plc, Vectura Group plc, Inion Ltd, ProStrakan Group plc, Alizyme plc Cardiomag Imaging Inc, GeneMedix plc, GW Pharmaceuticals plc, Akers Bioscience Inc and CustomVis plc.

Top